ABBV-637 + ERAS-801 for Glioblastoma
What You Need to Know Before You Apply
What is the purpose of this trial?
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, you cannot be on enzyme-inducing anti-epileptic drugs or certain other medications that interact with the study drugs. It's best to discuss your current medications with the study team to see if any changes are needed.
What data supports the effectiveness of the treatment ABBV-637 + ERAS-801 for Glioblastoma?
While there is no direct data on ABBV-637 + ERAS-801, research on similar treatments like rindopepimut shows promising results in glioblastoma by targeting specific mutations in the tumor, leading to improved survival rates. Additionally, oncolytic virus therapies have shown potential in creating strong immune responses against glioblastoma, suggesting that innovative approaches can be effective.12345
Who Is on the Research Team?
Thomas Kaley, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for individuals with recurrent glioblastoma, a type of brain cancer. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be required to have tried standard treatments first.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ABBV-637 or ABBV-155 in combination with ERAS-801, with additional standard treatments for newly diagnosed patients
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ABBV-155
- ABBV-637
- ERAS-801
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor